Promising CAR-T Immunotherapy Targets Aggressive T-Cell Cancers
Researchers at Washington University School of Medicine in St. Louis have spearheaded an international phase 1/2 clinical trial that demonstrates encouraging outcomes from a novel immunotherapy approach aimed at combating aggressive blood cancers, with side effects that remain largely controllable.…